» Authors » Junyong Wu

Junyong Wu

Explore the profile of Junyong Wu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 301
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang Y, Tang T, Li Y, Wu J, Liu X, Xiang D, et al.
Int J Nanomedicine . 2025 Mar; 20:2743-2759. PMID: 40066322
Objective: Photodynamic therapy (PDT) is a promising strategy with significant clinical application potential for tumor treatment. However, the tumor hypoxia and limited efficacy against tumor metastasis present significant limitations in...
2.
Zhou M, Han R, Xu W, Hao X, Peng Y, Tang Y, et al.
Biomater Res . 2025 Mar; 29:0149. PMID: 40040956
Cancer continues to pose remarkable medical challenges worldwide. While current cancer therapies can lead to initial clinical improvement, they are often followed by recurrence, metastasis, and drug resistance, underscoring the...
3.
Hao X, Tang Y, Xu W, Wang M, Liu J, Li Y, et al.
J Nanobiotechnology . 2025 Jan; 23(1):14. PMID: 39810130
Glioblastoma multiforme (GBM) is characterized by pronounced immune escape and resistance to chemotherapy-induced apoptosis. Preliminary investigations revealed a marked overexpression of gasdermin E (GSDME) in GBM. Notably, cisplatin (CDDP) demonstrated...
4.
Xu W, Zeng Z, Tang Y, Tian J, Hao X, Sun P, et al.
J Nanobiotechnology . 2024 Dec; 22(1):798. PMID: 39725974
Chemotherapy is still one of the major approaches in triple-negative breast cancer (TNBC) treatment. The development of new formulations for classic chemotherapeutic drugs remains interests in studies. Camptothecin (CPT) is...
5.
Wu J, Hao X, Qi L, Xu W, Yin C, Tang Y, et al.
Acta Biomater . 2024 Dec; 193:348-361. PMID: 39710219
Osteosarcoma tissues demonstrated elevated expression of proteins (FDX1 and DLAT) integral to cuproptosis in our preliminary study, indicating the potential effectiveness of anti-tumor strategies predicated on this process. Nevertheless, the...
6.
Wang Y, Li S, Li W, Wu J, Hu X, Tang T, et al.
Nanomedicine (Lond) . 2024 Sep; 19(28):2335-2355. PMID: 39316570
This study aimed to construct an ischemic cardiomyocyte-targeted and ROS-responsive drug release system to reduce myocardial ischemia-reperfusion injury (MI/RI). We constructed thioketal (TK) and cardiac homing peptide (CHP) dual-modified liposomes...
7.
Wang Y, Li F, Wei S, Li W, Wu J, Li S, et al.
Int J Nanomedicine . 2024 Aug; 19:7997-8014. PMID: 39130683
Purpose: Mitochondrial damage may lead to uncontrolled oxidative stress and massive apoptosis, and thus plays a pivotal role in the pathological processes of myocardial ischemia-reperfusion (I/R) injury. However, it is...
8.
Hao X, Jiang B, Wu J, Xiang D, Xiong Z, Li C, et al.
J Control Release . 2024 Jul; 373:640-651. PMID: 39084467
Bone metastasis, a prevalent occurrence in primary malignant tumors, is often associated with a grim prognosis. The bone microenvironment comprises various coexisting cell types, working together in a coordinated manner....
9.
10.
Liu J, Wu J, Chen T, Yang B, Liu X, Xi J, et al.
Small . 2024 Apr; 20(35):e2400954. PMID: 38676336
In the progression of X-ray-based radiotherapy for the treatment of cancer, the incorporation of nanoparticles (NPs) has a transformative impact. This study investigates the potential of NPs, particularly those comprised...